Interleukin Genetics Inc. Initiates Clinical Studies for Its Periodontal Disease Predictive Genetic Test in Chinese Populations

WALTHAM, Mass., Nov. 1, 2011 /PRNewswire/ -- Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that the Company has initiated two clinical studies to demonstrate the utility of its new PST^® genetic test in the ethnic Chinese population. The programs are being conducted in collaboration with Professor Chi-Cheng Tsai of Kaohsiung Medical University and Professor Dong Chen at Shanghai Stomatological Disease Center.

“We are pleased to have initiated these two studies with our collaborators in China. Demonstration of the utility of the PST in Asian populations will be important for expanding the use of our test,” said Lewis H. Bender, Chief Executive Officer of Interleukin Genetics. “Further, we believe that the ongoing clinical study of our PST test being conducted by the University of Michigan has the potential to make a major impact on improving oral health care in the U.S.”

In addition, the Company announced today that Chief Scientific Officer Dr. Kenneth Kornman will present “Impact of Risk Assessment on Diagnosis and Management of Periodontal Disease” on November 15 at the 2011 American Academy of Periodontology’s Annual Meeting in Miami. Dr. Kornman will also present “Risk Factors for Recurrent Periodontitis” at the Harvard University School of Dental Medicine on November 30.

“Presenting improved methods to manage patients using diagnostic and prognostic technologies to the dental and periodontal community is important to advancing the science in this field,” said Dr. Kornman. “We are working with key academic opinion leaders to introduce the benefits of using these new tools.”

About PST^® and Current Clinical Studies

PST identifies individuals with increased risk for severe and progressive periodontal disease and significant tooth loss based on a proprietary panel of genetic variations that predispose an individual to over-express inflammation. In August 2010, Interleukin Genetics announced the initiation of a landmark clinical study on risk factors predictive of periodontal disease progression to tooth loss using a new version of the PST genetic test. This clinical study - being conducted at the University of Michigan School of Dentistry and led by Dr. William Giannobile, Director of the Michigan Center for Oral Health Research - is designed to test whether risk factors, including genetic information, can guide more successful intervention and thus reduce the adverse outcomes of periodontal disease, such as tooth loss.

About Interleukin Genetics, Inc.

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health^® brand. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics’ flagship products include its proprietary PST^® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit http://www.ilgenetics.com.

Certain statements contained herein are “forward-looking” statements, including statements that the clinical studies have the potential to expand the use of the PST^® genetic test. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in the Interleukin Genetics’ annual report on Form 10-K for the year ended December 31, 2010 and other filings with the Securities and Exchange Commission. Interleukin Genetics disclaims any obligation or intention to update these forward-looking statements.

SOURCE Interleukin Genetics, Inc.